These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 13337026)

  • 1. [Inactivation and antigenicity of poliomyelitis virus type 2 (MEF-1 strain) treated with beta-propiolactone].
    D'ALESSANDRO G; ODDO FG; INSERILLO G
    Riv Ist Sieroter Ital; 1956; 31(1):65-8. PubMed ID: 13337026
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of beta-propiolactone for the preparation of virus vaccines. I. Selection of reaction conditions.
    POLLEY JR; GUERIN MM
    Can J Microbiol; 1957 Oct; 3(6):863-70. PubMed ID: 13472511
    [No Abstract]   [Full Text] [Related]  

  • 3. [Further research on the inactivation of poliomyelitis virus by beta-propiolactone].
    D'ALESSANDRO G; ODDO FG; INSERILLO G
    Riv Ist Sieroter Ital; 1956; 31(6):464-8. PubMed ID: 13408889
    [No Abstract]   [Full Text] [Related]  

  • 4. Antigenicity of beta-propiolactone-inactivated virus vaccines.
    LOGRIPPO GA; HARTMAN FW
    J Immunol; 1955 Aug; 75(2):123-8. PubMed ID: 13242811
    [No Abstract]   [Full Text] [Related]  

  • 5. The use of beta-propiolactone for the preparation of virus vaccines. II. Antigenicity.
    POLLEY JR; GUERIN MM
    Can J Microbiol; 1957 Oct; 3(6):871-7. PubMed ID: 13472512
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of beta-propiolactone on complement-fixing antigens of St. Louis encephalitis virus.
    FINKELSTEIN RA; SULKIN SE
    Proc Soc Exp Biol Med; 1957 May; 95(1):112-5. PubMed ID: 13432007
    [No Abstract]   [Full Text] [Related]  

  • 7. Serological response in chickens to beta-propiolactone treated Newcastle disease virus.
    MACK WN; CHOTISEN A
    Proc Soc Exp Biol Med; 1956 Feb; 91(2):288-90. PubMed ID: 13297779
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antigenic and vaccinating power of Newcastle virus inactivated by beta-propiolactone].
    LEPINE P; ATANASIU P
    Ann Inst Pasteur (Paris); 1956 Jul; 91(1):100-2. PubMed ID: 13340335
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined use of ultraviolet irradiation and beta propiolactone sterilization of sera infected with a virus.
    SMOLENS J; STOKES J
    Proc Soc Exp Biol Med; 1954 Jul; 86(3):538-9. PubMed ID: 13194713
    [No Abstract]   [Full Text] [Related]  

  • 10. The effects of beta-propiolactone on the metabolism of Candida albicans.
    GALE GR
    J Infect Dis; 1955; 96(3):250-8. PubMed ID: 14392370
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of beta-propiolactone on bacterial spores.
    CURRAN HR; EVANS FR
    J Infect Dis; 1956; 99(3):212-8. PubMed ID: 13376916
    [No Abstract]   [Full Text] [Related]  

  • 12. Immuno-inactivation of poliovirus.
    GARD S
    Arch Gesamte Virusforsch; 1957; 7(5):449-60. PubMed ID: 13521959
    [No Abstract]   [Full Text] [Related]  

  • 13. The carcinogenicity of beta-propiolactone for mouseskin.
    GLENDENNING OM; ROE FJ
    Br J Cancer; 1956 Jun; 10(2):357-62. PubMed ID: 13364127
    [No Abstract]   [Full Text] [Related]  

  • 14. The activity of human regains exposed to the disinfectant, beta-propiolactone.
    FLICK JA; FEINBERG RJ
    J Allergy; 1955 May; 26(3):262-7. PubMed ID: 14366906
    [No Abstract]   [Full Text] [Related]  

  • 15. The inhibition of respiration of certain dermatophytes by beta propiolactone.
    GALE GR
    J Invest Dermatol; 1954 Jan; 22(1):1-3. PubMed ID: 13118247
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of poliovirus particles of different antigenicity by specific agglutination as seen in the electron microscope.
    HUMMELER K; ANDERSON TF; BROWN RA
    Virology; 1962 Jan; 16():84-90. PubMed ID: 14449962
    [No Abstract]   [Full Text] [Related]  

  • 17. [Isolation and investigation of the IV immunological type of poliomyelitis virus].
    CHUMAKOV MP; VOROSHILOVA MK; ZHEVANDROVA VI; MIRONOVA LL; ITSELIS FG; ROBINZON Ia
    Vopr Virusol; 1956; 1(1):16-9. PubMed ID: 13352956
    [No Abstract]   [Full Text] [Related]  

  • 18. Production of poliomyelitis virus with combined antigenic characteristics of type I and type II.
    SPRUNT K; MOUNTAIN IM; REDMAN WM; ALEXANDER HE
    Virology; 1955 Jul; 1(2):236-49. PubMed ID: 13267990
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunological strain specificity within type 1 poliovirus.
    GARD S
    Bull World Health Organ; 1960; 22(3-4):235-42. PubMed ID: 13826481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of type 2 poliomyelitis viruses. II. Antigenic differences relating to 18 type 2 strains.
    KAMITSUKA P; LENAHAN M; WENNER HA
    J Immunol; 1956 Oct; 77(4):220-31. PubMed ID: 13376893
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.